LOS ANGELES, Aug. 11 /PRNewswire-FirstCall/ -- Vista Partners announced today that it has initiated coverage on Vicor Technologies, Inc. (OTC Bulletin Board: VCRT) with a twelve month price target of $2.96. Ross Silver, Principal Analyst of Vista Partners stated, "Vicor has already established proof of concept with the FDA via their 510 (k) approval in December 2008. The next step for Vicor is the realization of revenues and the market potential for Vicor's products is greater than $8 billion. Based on the depth and quality of the Company's product offerings along with their top tier management team, Scientific Advisory Board and Board of Directors, it is easy to get excited about the Company's prospects." To download a free copy of the report, please visit the Vista Partners website, www.vistap.com and click on the download research icon.
About Vista Partners:
Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at www.vistap.com.
About Vicor Technologies, Inc.:
Vicor Technologies is a development-stage biotechnology company creating innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i.) The PD2i is a deterministic, non-linear measure that analyzes electrophysiological potentials to predict future pathological events with a high degree of accuracy in target populations.
Vicor currently has three products employing the PD2i algorithm. The PD2i Analyzer, which has FDA 510(k) marketing clearance, measures heart rate variability and will be commencing a clinical trial to determine its efficacy to detect the presence of diabetic autonomic neuropathy (DAN). The PD2i VS (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA (Cardiac Analyzer), in multiple clinical trials, identifies patients at risk of suffering sudden cardiac death.
Vicor anticipates additional applications employing the PD2i to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.
CONTACT:
Emily Gilbert
+1-310-744-5268
info@vistap.com
SOURCE Vista Partners
